Evidence map›Paper›PMID 39239542›Full record

ArticleInternational journal of medical sciences2024

Multiple Comprehensive Analyses Identify Lysine Demethylase KDM as a Potential Therapeutic Target for Pancreatic Cancer.

Wan-Jou Shen, Hsuan-Min Kao, Chih-Yang Wang, Rubina Kousar, Jing-Shan Lin, Ching-Chung Ko, Hung-Yun Lin, Hoang Dang Khoa Ta, Gangga Anuraga, Do Thi Minh Xuan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wan-Jou ShenGraduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan.
Hsuan-Min KaoDepartment of Geriatric, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City 600566, Taiwan.
Chih-Yang WangGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Rubina KousarDepartment of Biological Science and Technology, China Medical University, Taichung 40676, Taiwan.
Jing-Shan LinDepartment of Biological Science and Technology, China Medical University, Taichung 40676, Taiwan.
Ching-Chung KoDepartment of Medical Imaging, Chi-Mei Medical Center, Tainan, Taiwan.
Hung-Yun LinGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Hoang Dang Khoa TaPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.
Gangga AnuragaPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.
Do Thi Minh XuanFaculty of Pharmacy, Van Lang University, 69/68 Dang Thuy Tram Street, Ward 13, Binh Thanh District, Ho Chi Minh City 70000, Vietnam.
Sachin KumarGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Sanskriti DeyGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Ngoc Phung LyGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Wei-Jan WangDepartment of Biological Science and Technology, China Medical University, Taichung 40676, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PC) is a challenging and heterogeneous disease with a high mortality rate. Despite advancements in treatment, the prognosis for PC patients remains poor, with a high chance of disease recurrence. Biomarkers are crucial for diagnosing cancer, predicting patient prognosis and selecting treatments. However, the current lack of effective biomarkers for PC could contribute to the insufficiency of existing treatments. These findings underscore the urgent need to develop novel strategies to fight this disease. This study utilized multiple comprehensive bioinformatic analyses to identify potential therapeutic target genes in PC, focusing on histone lysine demethylases (KDMs). We found that high expression levels of KDM family genes, particularly KDM1A, KDM5A and KDM5B, were associated with improved overall survival in the cohort. Furthermore, the infiltration of various immune cells, including B cells, neutrophils, CD8

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticJumonji Domain-Containing Histone DemethylasesPancreatic NeoplasmsCell ProliferationComputational BiologyF-Box ProteinsHistone DemethylasesHumansMolecular Targeted TherapyNuclear ProteinsPrognosisRepressor ProteinsRetinoblastoma-Binding Protein 2Wnt Signaling PathwayBiomarkers, TumorF-Box ProteinsHistone DemethylasesJumonji Domain-Containing Histone DemethylasesKDM1A protein, humanKDM5A protein, humanKDM5B protein, humanNuclear ProteinsRepressor ProteinsRetinoblastoma-Binding Protein 2

Identifiers

PMID39239542
PMCPMC11373554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.